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a Us database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease David 
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the US, with an estimated prevalence of 25 million and an annual death rate of 124,477. 1, 2 Maintenance therapies for COPD recommended by clinical guidelines include long-acting β 2 -adrenergic agonists (LABAs) alone, inhaled corticosteroid (ICS)-LABA combinations, and anticholinergic agents.
Tiotropium bromide inhalation powder, approved for COPD treatment in the US in 2004, is indicated for longterm, once-daily maintenance treatment of bronchospasm associated with COPD; it is also indicated to reduce COPD exacerbations. 5 To date, no study has compared health care-resource utilization and costs of COPD patients prior to initiating BFC versus tiotropium. The objective of this study was to describe and evaluate demographic and clinical characteristics and health care utilization and costs in COPD patients initiating BFC or tiotropium bromide in the 12 months prior to treatment initiation.
Materials and methods study design, population, and data source
This cross-sectional study employed administrative claims data to describe key characteristics of COPD patients initiating BFC or tiotropium therapy between March 1, 2009 and January 31, 2012 (intake period). Patients were identified using Generic Product Identifier codes: BFC (4420990241) and tiotropium (44100080100120). The index date was defined as the processing date of the first pharmacy claim for COPD maintenance medication, and patients were assigned to either the BFC or tiotropium group depending on their index prescription fill. The BFC group consisted of BFC initiators who received no tiotropium or ICS-LABA in the 12 months prior to the index date, and to ensure patients were initiating only one of the study medications, had no tiotropium fills within 15 days of initiating BFC therapy. Similarly, patients in the tiotropium group received neither tiotropium nor ICS-LABA in the 12 months prior to the index date, and did not fill an ICS-LABA prescription within 15 days of starting tiotropium treatment.
All study data were queried from the HealthCore Integrated Research Database, a repository of a broad spectrum of medical, pharmacy, and laboratory information on more than 46 million health plan members from across the US. The service models of the 14 commercial health plans included in the database encompass health maintenance organizations, point of service, preferred provider organizations, and indemnity plans. Throughout this study, researchers' access was limited to deidentified data to ensure patient privacy and confidentiality. Strict measures were observed to ensure full compliance with the Health Insurance Portability and Accountability Act of 1996.
Inclusion criteria
Patients had to be $40 years old at the index date, have COPD and at least one prescription fill for BFC or tiotropium during the intake period. COPD diagnostic criteria included the presence of at least one inpatient claim with a primary diagnosis of COPD and/or at least one emergency department (ER) claim with a COPD diagnosis and/or two other medical claims with a COPD diagnosis, including outpatient visits or inpatient visits with a nonprimary COPD diagnosis (based on the International Classification of Diseases, ninth revision, clinical modification [ICD-9-CM] diagnosis codes 491.xx, 492.xx, and 496.xx). Patients were also required to have at least 12 months of continuous health plan coverage for medical and pharmacy benefits prior to the index date.
exclusion criteria
Excluded were patients with a diagnosis of respiratory tract cancer (larynx, trachea, pleura, or lung) during the 12-month preindex date, as indicated by the presence of two medical claims, at least 30 days apart (ICD-9-CM codes 161.xx, 162.xx, 163.xx, 231.xx, and 197.0x).
Measures
Important measures in this analysis included indicators of COPD disease activity, such as use of respiratory medications (ICS, LABA, ICS-LABA combination, tiotropium, leukotriene-receptor antagonists, theophylline, roflumilast, short-acting β 2 -agonists [SABAs], short-acting muscarinic antagonists [SAMAs], SABA-SAMA combination, and oral corticosteroids [OCS]), prior COPD exacerbations, COPDrelated health care-resource utilization (inpatient visits, ER visits, outpatient visits, and other places of service with an ICD-9-CM diagnosis code for COPD), and COPD-related procedures (chest X-rays, chest computed tomography scans, pulmonary function tests, and home oxygen use). Costs of COPD-related health care utilization and respiratory medications were also analyzed. COPD exacerbations were analyzed as a single outcome and by each individual component: COPDrelated inpatient hospitalizations, ER visits, and OCS prescription fills. Other indicators of overall health status included all-cause health care-resource utilization and costs, presence of chronic comorbid conditions, and total medication use.
statistical analysis
The frequency and proportion of all categorical and dichotomous variables, along with odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Significant 
Results

Preindex demographics and clinical characteristics
A total of 6,940 and 10,831 BFC-and tiotropium-initiated patients, respectively, were identified. There were some differences in demographic characteristics between the two Notes: *Chi-square test odds ratio was used for categorical variables, and student's t-test difference in means used for continuous variables. statistical comparisons compared group 1 to group 2 (reference group), ie, mean difference = mean (group 1) − mean (group 2), and odds ratio = odds (group 1)/odds (group 2). Abbreviations: BFC, budesonide-formoterol; ICs, inhaled corticosteroid; laBa, long-acting β 2 -adrenergic agonist; SD, standard deviation; CI confidence interval; HMO, health maintenance organization; PPO, preferred provider organization; CDhP, consumer-driven health plan. 
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Characteristics of patients initiating COPD therapy number of visits was smaller for BFC patients (4.1 versus 4.6, mean difference 0.52, CI 0.33-0.70). A greater proportion of BFC-treated patients had outpatient visits that were associated with an OCS or antibiotic prescription fill (44.0% BFC versus 33.0% tiotropium, OR 1.59, CI 1.49-1.69). As shown in Figure 1 , the proportions of COPD-related inpatient hospitalizations were generally equal between the two groups, while ER visits were slightly more common in tiotropium patients (7.7% BFC versus 8.6% tiotropium, OR 0.89, CI 0.80-0.99). As indicated in Figure 2 , there were only small differences between the two groups in the utilization of COPD-related procedures: chest X-rays 
Preindex COPD exacerbation rates by age-group
In the year prior to initiation of COPD maintenance medication, patients new to tiotropium were less likely to have a COPD exacerbation compared with those new to BFC 
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Kern et al (50.2% BFC versus 40.4% tiotropium). The difference in COPD exacerbation rates was driven by differences in OCS use, while COPD-related inpatient hospitalization and ER visits were comparable between the groups. Similar results were observed when exacerbation rates were calculated for those ,65 and $65 years of age (Table 4 ). In both treatment groups, patients ,65 years old had higher preindex rates of COPD exacerbations compared to those $65 years old. Age-adjusted exacerbation-rate differences were more pronounced within BFC patients (53.6% of patients aged ,65 years with at least one prior exacerbation compared with 46.3% of patients $65) than tiotropium patients (42.8% versus 38.4%).
Preindex COPD and all-causerelated health care costs 
Discussion
Therapeutic guidelines recommend the treatment and prevention of exacerbations as the main goal of COPD management. 3, 6 With the availability of different therapeutic options, the decision to initiate COPD maintenance medication is often determined by presenting symptoms, clinical history, and the risk assessment of future COPD exacerbations. [7] [8] [9] This study is the first to assess differences in characteristics of COPD patients before they initiated BFC or tiotropium using claims data from a large geographically diverse population. 
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As a result, there is a dearth of comparable study data in the literature with which to evaluate our results. While studies have compared patients who initiated COPDcontroller medications, they have not studied BFC relative to tiotropium, nor have they focused on the baseline period, before patients are indexed on maintenance therapy. 10, 11 While there are studies that have incorporated one of the agents we assessed, 12 it would appear that no published study to date has compared preindex demographics, clinical characteristics, chronic comorbidities, respiratory medication fill, COPD-related health care utilization, exacerbation rates, and COPD and all-cause health care costs during the preindex period for patients initiating BFC and tiotropium as maintenance therapy. Current study results indicate that COPD patients who initiate maintenance therapy with BFC may be different than those who initiate tiotropium. Patients who initiated BFC in this study had a higher prevalence of chronic respiratory conditions and higher utilization of respiratory medication at baseline. BFC initiators had a higher percentage of COPD exacerbations in the 12 months preindex for both the ,65-and $65-year age-groups compared with patients indexing on tiotropium. The majority of COPD exacerbations were captured by OCS prescription fills, which contributed most to the differences observed between the groups.
BFC is also indicated for asthma, which likely contributes to the higher proportion of patients in the BFC group with a prior asthma diagnosis compared to tiotropium. Greater respiratory disease comorbidities in the BFC group also likely accounts for the increased utilization of respiratory medications preindex, including but not limited to OCS. Such comorbid conditions as allergic rhinitis, sinusitis, and gastroesophageal reflux disease were also more prevalent in the BFC-treated population. Conversely, the observed higher overall health care costs among tiotropium initiators may be due to their older age and the higher prevalence of comorbid cardiovascular disease.
Among the proxy measures for exacerbations in this study were COPD-related inpatient hospitalizations and ER visits and OCS fills. While antibiotic usage may also be used as a proxy for COPD exacerbations, it is not specific to COPD. In this analysis, COPD-related visits with OCS or antibiotic prescription fills occurring within 10 days of the visit were also captured. This broadened definition of an exacerbation did not result in the inclusion of additional patients who were not already captured by the initial definition. Prior exacerbations are predictive of future exacerbations; as a consequence, 13, 14 it would be informative to control for prior exacerbations in analyses of postindex exacerbation rates in future comparative effectiveness studies. 15 
limitations
This study adds new insights on the clinical characteristics of COPD patients prior to initiation of COPD maintenance medication. The interpretation of findings should be within the context of limitations inherent to the use of administrative claims databases. [16] [17] [18] [19] [20] [21] [22] Primarily, COPD-related health care-resource utilization is based on claims diagnosis; however, the actual visit may be due to routine follow-up and monitoring.
Claims data do not include clinical indicators of COPD disease severity (ie, symptoms or lung-function data), and thus only measures of disease activity were analyzed (ie, COPD-related health care utilization and costs). Smoking status, a primary cause of COPD, is also unknown in this data source. Because administrative claims data may be subject to incorrect or rule-out diagnoses, the diagnostic criteria for COPD required more than one claim containing a diagnosis of COPD for most cases, the exceptions being an inpatient hospitalization with a primary COPD diagnosis or ER visit with a COPD diagnosis.
For the pharmacy claims, a prescription-fill date was recorded as the beginning date of treatment, which might not have been the actual date a patient started therapy. Patients aged 65 years and older were underrepresented in the database used for this study. Overall, these findings may have limited applicability beyond similar managed care patient populations.
Conclusion
Patients initiating BFC or tiotropium therapy had important differences prior to the start of treatment. COPD patients initiating BFC had a higher proportion of COPD exacerbations before starting controller therapy compared with tiotropium initiators, which may be indicative of more severe disease or attributable to a higher prevalence of comorbid respiratory disorders in this group. The higher overall health care costs among tiotropium-treated patients could be a reflection of a greater degree of cardiovascular disease within this group. A much higher prevalence of asthma in the BFC population was observed, which may have influenced such characteristics as other comorbid respiratory conditions and concomitant respiratory medication use. Such differences among patient groups must be considered in outcome studies evaluating the comparative effectiveness of different therapies, as they may influence patients' probability of initiating and benefiting from a particular treatment.
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